



Contacts: Cumbre Inc., Dallas
Bob England
(214) 648-3898

Cumbre Establishes Scientific Advisory Board

Dallas –(BW HealthWire) – October 9, 2001 -- Cumbre Inc., a Dallas-based biopharmaceutical company, announced today the formation of a world class Scientific Advisory Board.

Members of the Scientific Advisory Board will also serve as consultants to Cumbre in their respective areas of expertise.

Focused on antibiotic and antifungal drug discovery, Cumbre was spun off from Tularik Inc. (Nasdaq:TLRK) in February 2001. The company's scientific platform combines a proteomics-based drug discovery technology with target-directed screens and an advanced lead compound series contributed by Tularik. Cumbre recently completed a \$26 million private placement.

“I am delighted with the distinguished team of scientists who have joined the advisory board and who will help us in our mission of discovering antimicrobial agents,” said Dr. Richard M. Losick, chairman of the advisory board, and a founder of Cumbre. Dr. Losick is a Professor of Molecular & Cellular Biology at Harvard University where he is a world leader in microbial gene regulation. Dr. Losick is a member of the National Academy of Sciences and the American Academy of Arts and Sciences.

The remaining members of the Cumbre Scientific Advisory Board are:

- Stephen J. Benkovic, Ph.D. is Professor of Chemistry at Penn State University, a member of the National Academy of Sciences and former head of the Research and Development Board of SmithKline Beecham. His research has emphasized the study of the mechanisms of enzyme catalyzed reactions.
- Michael S. Brown, M.D. is Professor of Medicine and Genetics in the Department of Molecular Genetics at University of Texas Southwestern Medical Center at Dallas. Working as a team, with Dr. Joseph L. Goldstein, Dr. Brown pioneered a multidisciplinary approach to the study of hypercholesterolemia by using a combination of biochemistry, somatic cell genetics, molecular biology and, most recently, gene regulation and cell biology. In 1985, Drs. Brown and Goldstein were awarded the Nobel Prize in Medicine for their work in the regulation of cholesterol

metabolism, and in 1988 they received the National Medal of Science. Dr. Brown was elected to the National Academy of Sciences in 1980.

- E. J. Corey, Ph.D. is Professor of Chemistry at Harvard University and is a leader in organic synthetic chemistry, including applications for manufacturing of pharmaceuticals and applying computers to organic chemical problems. In 1988, Dr. Corey received the National Medal of Science and in 1990, was awarded the Nobel Prize in Chemistry for his development of the theory and methodology of organic synthesis.
- Gary M. Dunny, Ph.D. is Professor of Microbiology at University of Minnesota. Dr. Dunny's research has emphasized the regulation of expression of genetic transfer functions and the regulation of virulence in gram-positive bacteria. He has been especially interested in regulatory mechanisms involving cell-cell signaling by peptide mating pheromones and mechanisms involving novel RNA regulators.
- Michael S. Gilmore, Ph.D. is Professor of Microbiology and Immunology, and Vice President of Research at University of Oklahoma Health Sciences Center. His recent work has focused on molecular pathogenesis of diseases caused by antibiotic-resistant gram-positive bacteria and inflammation in the pathogenesis of infectious disease. His work has been recognized by election to the American Academy of Microbiology and the award of a Fogarty Senior International Fellowship to Cambridge University
- Joseph L. Goldstein, M.D. is Professor and Chairman of the Department of Molecular Genetics at University of Texas Southwestern Medical Center at Dallas. Dr. Goldstein, along with Dr. Brown, pioneered a multidisciplinary approach to the study of hypercholesterolemia by using a combination of biochemistry, somatic cell genetics, molecular biology and, most recently, gene regulation and cell biology. In 1985, Drs. Brown and Goldstein were awarded the Nobel Prize in Medicine for their work in the regulation of cholesterol metabolism, and in 1988 they received the National Medal of Science. Dr. Goldstein was elected to the National Academy of Sciences in 1980.
- Robert Tjian, Ph.D. is an investigator of the Howard Hughes Medical Institute at the University of California, Berkeley. He is one of the world leaders in the field of transcription factor biochemistry and has been a member of the National Academy of Sciences since 1991. Dr. Tjian is a founder of Tularik and has served as Chairman of its Scientific Advisory Board since inception.

“We are honored to have such an esteemed group of advisors,” said Bob England, Cumbre's President and CEO. “I look forward to benefiting from their guidance.”

About Cumbre

Cumbre is a Dallas-based biopharmaceutical company focused on discovery, development and commercialization of new classes of antibacterial and antifungal drugs.

This press release contains “forward-looking” statements. For this purpose, any statements contained in this press release that are not statements of historical fact may be

deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “intend” and similar expressions are intended to identify forward-looking statements.